CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

NCT ID: NCT05306288

Last Updated: 2025-06-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

11935 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-07

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CASCADE-LUNG is a multisite, prospective, observational, blood specimen collection study in the elevated-risk lung cancer screening population. The primary objective is to demonstrate the performance characteristics, including sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the DELFI Lung Cancer Screening Test (DLCST).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

DELFI identifies circulating tumor DNA (ctDNA) to detect cancer. Participants will be enrolled into the DELFI-L201 study after informed consent and eligibility is confirmed. The study purpose is to validate the performance of the DELFI-based test for the detection of lung cancer among individuals eligible for routine lung cancer screening. Participants will have blood collected and medical record review at baseline and will have medical record reviews at additional timepoints.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Individuals with elevated-risk lung cancer (screening population)

Blood Sample Collection

Intervention Type OTHER

Subjects enrolled in DELFI-L201 will have blood specimens collected (\~30 mL) at enrollment or up to 30 days after enrollment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Sample Collection

Subjects enrolled in DELFI-L201 will have blood specimens collected (\~30 mL) at enrollment or up to 30 days after enrollment.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All subjects

1. Ability to understand and provide written informed consent
2. Age ≥ 50 years
3. Current or former smoker
4. ≥ 20 pack-years (pack years = number of packs per day × number of years smoked)
5. An initial or annual follow-up lung cancer screening chest CT planned/scheduled within 30 days after enrollment (i.e., enrollment chest CT scan)

Exclusion Criteria

* All subjects

1. Evidence of any diagnosed cancer (including prior lung cancer) other than non-melanoma skin cancer or carcinoma in situ within 2 years prior to enrollment
2. Prior systemic therapy, definitive therapy, radiation, or surgical resection for any cancer diagnosis within 2 years prior to enrollment (with the exception of surgery for nonmelanoma skin cancer and biopsies)
3. Any history of hematologic malignancy or myelodysplasia within 2 years prior to enrollment
4. Any history of organ tissue transplantation
5. Any history of blood product transfusion within 120 days prior to enrollment
6. Current pregnancy
7. Any condition that in the opinion of the Investigator should preclude the participant's participation in the study
8. Past or current participation in any clinical study sponsored by DELFI Diagnostics or any history of a LDT (Laboratory Developed Test) for early detection of lung cancer by DELFI Diagnostics
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Delfi Diagnostics Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cullman Clinical Trials

Cullman, Alabama, United States

Site Status

Science 37 (nationwide digital enrollment)

Culver City, California, United States

Site Status

Providence Facey Medical Foundation

Mission Hills, California, United States

Site Status

Hoag Hospital

Newport Beach, California, United States

Site Status

Paradigm Clinical Research Center, Inc.

Redding, California, United States

Site Status

San Francisco VA

San Francisco, California, United States

Site Status

Clinical Research of California LLC

Walnut Creek, California, United States

Site Status

SCL Health Research Institute, St. Mary's

Grand Junction, Colorado, United States

Site Status

Paradigm Clinical Research Center

Wheat Ridge, Colorado, United States

Site Status

Stamford Health

Stamford, Connecticut, United States

Site Status

Advanced Research

Boynton Beach, Florida, United States

Site Status

Morton Plant Hospital

Clearwater, Florida, United States

Site Status

SIMEDHealth, LLC

Gainesville, Florida, United States

Site Status

Galenus Group

Lehigh Acres, Florida, United States

Site Status

Renstar Medical Research

Ocala, Florida, United States

Site Status

United Medical Research

Port Orange, Florida, United States

Site Status

American Clinical Trials, LLC.

Acworth, Georgia, United States

Site Status

Centricity Research Columbus Piedmont

Columbus, Georgia, United States

Site Status

ClinCept, LLC

Columbus, Georgia, United States

Site Status

Coastal Heritage Clinical Research

Hinesville, Georgia, United States

Site Status

Centricity Research Gwinnett Pulmonology

Lawrenceville, Georgia, United States

Site Status

Centricity Research Rincon Pulmonology

Rincon, Georgia, United States

Site Status

OSF Saint Francis Medical Center

Peoria, Illinois, United States

Site Status

Springfield Clinic

Springfield, Illinois, United States

Site Status

St. Elizabeth Healthcare

Edgewood, Kentucky, United States

Site Status

Ochsner

New Orleans, Louisiana, United States

Site Status

Johns Hopkins

Baltimore, Maryland, United States

Site Status

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

Pulmonary Research Institute of Southeast Michigan

Farmington Hills, Michigan, United States

Site Status

Minneapolis VA

Minneapolis, Minnesota, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Hannibal Regional Healthcare System

Hannibal, Missouri, United States

Site Status

Washington University

St Louis, Missouri, United States

Site Status

Missouri Baptist Medical Center

St Louis, Missouri, United States

Site Status

Somnos Clinical Research

Lincoln, Nebraska, United States

Site Status

Internal Medicine Associate

Bridgeton, New Jersey, United States

Site Status

CHRISTUS St. Vincent Regional Medical Center

Santa Fe, New Mexico, United States

Site Status

University of Rochester Medical Center

Rochester, New York, United States

Site Status

SUNY Upstate Medical University

Syracuse, New York, United States

Site Status

University of North Carolina Chapel Hill

Chapel Hill, North Carolina, United States

Site Status

Duke University

Durham, North Carolina, United States

Site Status

Durham VA

Durham, North Carolina, United States

Site Status

Coastal Carolina Health Care, P.A.

New Bern, North Carolina, United States

Site Status

University of Cincinnati Medical Center

Cincinnati, Ohio, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

Hightower Clinical

Oklahoma City, Oklahoma, United States

Site Status

Northwest Research Center

Portland, Oregon, United States

Site Status

Oregon Health Sciences University

Portland, Oregon, United States

Site Status

Clinical Research Associates of Central Pa, LLC

DuBois, Pennsylvania, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Site Status

Pittsburgh VA Healthcare System

Pittsburgh, Pennsylvania, United States

Site Status

Allegheny Health Network

Pittsburgh, Pennsylvania, United States

Site Status

Ralph H Johnson VA

Charleston, South Carolina, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

LLM Research

Myrtle Beach, South Carolina, United States

Site Status

Baptist Clinical Research Institute

Memphis, Tennessee, United States

Site Status

Greater Heights Memorial Pulmonary and Sleep

Houston, Texas, United States

Site Status

Houston Pulmonary Sleep and Allergy Associates

Houston, Texas, United States

Site Status

North Houston Cancer Clinics

Huntsville, Texas, United States

Site Status

CHRISTUS Trinity Clinic Pulmonary Medicine

Irving, Texas, United States

Site Status

R&H Clinical Research, Inc.

Katy, Texas, United States

Site Status

Lumi Research

Kingwood, Texas, United States

Site Status

Central Virginia VA Health System: Hunter Holmes McGuire

Richmond, Virginia, United States

Site Status

UW Medicine Valley Medical Center

Renton, Washington, United States

Site Status

Pan American Center for Oncology Trials

San Juan, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Puerto Rico

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DELFI-L201

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.